Cargando…

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma

BACKGROUND: The immunogenomic changes triggered by concurrent chemoradiation therapy (CCRT), a standard neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC), are unknown. We aimed to analyze the early immunogenomic changes in ESCC induced by CCRT and to correlate them...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Sehhoon, Joung, Je-Gun, Min, Yang Won, Nam, Jae-Yong, Ryu, Daeun, Oh, Dongryul, Park, Woong-Yang, Lee, Se-Hoon, Choi, Yoon La, Ahn, Jin Seok, Ahn, Myung-Ju, Park, Keunchil, Sun, Jong-Mu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524245/ https://www.ncbi.nlm.nih.gov/pubmed/31097034 http://dx.doi.org/10.1186/s40425-019-0609-x

Ejemplares similares

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
por: Noh, Jae Myoung, et al.
Publicado: (2015)

Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer
por: Lim, Sung Hee, et al.
Publicado: (2021)

Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Kim, Hana, et al.
Publicado: (2023)

Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2021)

Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery
por: Cho, Won Kyung, et al.
Publicado: (2016)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Long-term Survival in Non–Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
por: Kim, Hongsik, et al.
Publicado: (2022)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
por: Park, Song Ee, et al.
Publicado: (2019)

Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
por: Moon, Seung Hwan, et al.
Publicado: (2015)

Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system
por: Jung, Hyun Ae, et al.
Publicado: (2021)

Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
por: Park, Sehhoon, et al.
Publicado: (2022)

Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer()()
por: Yun, Jae Won, et al.
Publicado: (2018)

Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
por: Shin, Sumin, et al.
Publicado: (2020)

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment
por: Hwang, Soohyun, et al.
Publicado: (2021)

Prognostic Significance of the Post-Treatment Neutrophil-to-Lymphocyte Ratio in Pharyngeal Cancers Treated with Concurrent Chemoradiotherapy
por: Yun, Ji Min, et al.
Publicado: (2023)

Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
por: Kwon, Minsuk, et al.
Publicado: (2022)

Detection of Cancer Recurrence Using Systemic Inflammatory Markers and Machine Learning after Concurrent Chemoradiotherapy for Head and Neck Cancers
por: So, Yoon Kyoung, et al.
Publicado: (2023)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2023)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

Exome and transcriptome sequencing identifies loss of PDLIM2 in metastatic colorectal cancers
por: Oh, Bo Young, et al.
Publicado: (2017)

Trends in Survival Rates of Non–Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020
por: Chi, Sang Ah, et al.
Publicado: (2023)

Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
por: Kim, Hyunsu, et al.
Publicado: (2023)

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases
por: Ahn, Soomin, et al.
Publicado: (2016)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
por: Lee, Jiyun, et al.
Publicado: (2020)

The Effectiveness of Maintenance Pharmacotherapies for Non-Small Cell Lung Cancer
por: Ahn, Myung-Ju, et al.
Publicado: (2012)

EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
por: Kim, Hongsik, et al.
Publicado: (2023)

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
por: Jung, Hyun Ae, et al.
Publicado: (2022)

Predicting multi-class responses to preoperative chemoradiotherapy in rectal cancer patients
por: Gim, Jungsoo, et al.
Publicado: (2016)

Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
por: Lee, Kyung Hwa, et al.
Publicado: (2019)

Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
por: Noh, Jae Myoung, et al.
Publicado: (2016)

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations
por: Jun, Soojin, et al.
Publicado: (2023)

Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker
por: Ryu, Daeun, et al.
Publicado: (2016)

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
por: Byeon, Seonggyu, et al.
Publicado: (2016)

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
por: Lee, Kangkook, et al.
Publicado: (2020)

Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
por: Kim, Hongsik, et al.
Publicado: (2021)

Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion
por: Kim, Hakyoung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fsus5jptj31onkaic67p69q2hh